Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury

Cardiovascular Research

Volumn 103, Issue 4, 2014, Pages 521-529

  De Hoog, Vince C ^a   Timmers, Leo ^a   Van Duijvenvoorde, Amerik ^a   De Jager, Saskia C A ^a   Van Middelaar, Ben J ^a   Smeets, Mirjam B ^a   Woodruff, Trent M ^b   Doevendans, Pieter A ^a   Pasterkamp, Gerard ^a   Hack, C Erik ^a   De Kleijn, Dominique P V ^a,c,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

C5a receptor; Infarct size; Ischemia reperfusion; Leucocyte; Myocardial infarction

Indexed keywords

CASPASE 3; CASPASE 7; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CHIMERA; CONTROLLED STUDY; CORONARY REPERFUSION; ECHOCARDIOGRAPHY; EXPERIMENTAL CORONARY OCCLUSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; T LYMPHOCYTE; WILD TYPE; BAGG ALBINO MOUSE; CORONARY ARTERY OCCLUSION; DISEASE EXACERBATION; HEART MUSCLE INJURY; PROTEIN EXPRESSION; ANIMAL; DEFICIENCY; DISEASE MODEL; METABOLISM; MYOCARDIAL REPERFUSION INJURY;

ANIMALS; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; LEUKOCYTES; MALE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; RECEPTOR, ANAPHYLATOXIN C5A;

EID: 84907300023     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu153     Document Type: Article

References (44)

1. Bernink FJP, Timmers L, Beek AM, Diamant M, Roos ST, Van Rossum AC, Appelman Y. Progression in attenuating myocardial reperfusion injury: an overview. Int J Cardiol 2014; 170: 261-269.
2. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53: 31-47.
3. Hofmann U, Frantz S. How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res Cardiol 2013;108: 356.
4. Fujiu K, Nagai R. Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. Basic Res Cardiol 2013;108: 357.
5. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischaemia-reperfusion damage. Ann Med 2012;44: 205-217.
6. Diepenhorst GMP, van Gulik TM, Hack CE. Complement-mediated ischaemiareperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009;249: 889-899.
7. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels LA, Taylor SM. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006;374: 33-45.
8. Hill JH, Ward PA. The phlogistic role ofC3leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133: 885-900.
9. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Knostman JD, Hale SL. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 1978;61: 661-670.
10. Timmers L, Pasterkamp G, De Hoog VC, Arslan F, Appelman Y, De Kleijn DPV. The innate immune response in reperfused myocardium. Cardiovasc Res 2012;94: 276-283.
11. Rossen RD, Michael LH, Kagiyama A, Savage HE, Hanson G, Reisberg MA, Kim SH, Self D, Weakley S. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs cause release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res 1988;62: 572-584.
12. Rossen RD, Michael LH, Hawkins HK, Youker K, Dreyer WJ, Baughn RE, Entman ML. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res 1994;75: 546-555.
13. Nijmeijer R, Lagrand WK, Lubbers YTP, Visser CA, Meijer CJLM, Niessen HWM, Hack CE. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003;163: 269-275.
14. Krijnen PAJ, Ciurana C, Cramer T, Hazes T, Meijer CJLM, Visser CA, Niessen HWM, Hack CE. IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol 2005;58: 382-388.
15. ArmstrongPW, Granger CB, Adams PX, HammC, Holmes D, O'NeillWW, TodaroTG, Vahanian A, Van deWerf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 2007;297: 43-51.
16. Shernan SK, Fitch JCK, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004;77: 942-949.
17. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, ArmstrongPW. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108: 1176-1183.
18. Granger CB, MahaffeyKW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, RuzylloW, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108: 1184-1190.
19. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GGL, Abbate A, Agostoni P, Porto I, Andreotti F, Crea F, Banning AP. Pexelizumab in ischemic heart disease: a systematic reviewand meta-analysis on 15, 196 patients. J Thorac Cardiovasc Surg 2008;136: 884-893.
20. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011;48: 1631-1642.
21. Monk PN, Scola A-M, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007;152: 429-448.
22. Rabiet M-J, Huet E, Boulay F. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 2007;89: 1089-1106.
23. Wetsel RA. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995;7: 48-53.
24. Huang Y, Rabb H, Womer KL. Ischemia-reperfusion and immediate T cell responses. Cell Immunol 2007;248: 4-11.
25. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O'Donnell MP, Rabb H. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108: 1283-1290.
26. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61: 481-497.
27. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110: 159-173.
28. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
29. Wu MCL, Brennan FH, Lynch JPL, Mantovani S, Phipps S, Wetsel RA, Ruitenberg MJ, Taylor SM, Woodruff TM. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. PNAS 2013;110: 9439-9444.
30. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999;43: 860-878.
31. Schofield ZV, Woodruff TM, Halai R, Wu MC-L, Cooper MA. Neutrophils-A key component of ischemia-reperfusion injury. Shock 2013;40: 463-470.
32. Mueller M, Herzog C, Larmann J, Schmitz M, Hilfiker-kleiner D, Gessner JE, Theilmeier G. The receptor for activated complement factor 5 (C5aR) conveys myocardial ischemic damage by mediating neutrophil transmigration. Immunobiology 2013;5: 1-8.
33. Tang T-T, Yuan J, Zhu Z-F, Zhang W-C, Xiao H, Xia N, Yan X-X, Nie S-F, Liu J, Zhou S-F, Li J-J, Yao R, Liao M-Y, Tu X, Liao Y-H, Cheng X. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol 2012;107: 232.
34. Yang Z, Day Y-J, Toufektsian M-C, Xu Y, Ramos SI, Marshall M, French B, Linden J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006;114: 2056-2064.
35. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999;162: 4018-4023.
36. Kwan W, Van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res 2012;54: 247-253.
37. Lalli PN, StrainicMG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008;112: 1759-1766.
38. Dunkelberger JR, Song W-C. Role and mechanism of action of complement in regulating T cell immunity. Mol Immunol 2010;47: 2176-2186.
39. Van der Pals J, Koul S, Andersson P, Götberg M, Ubachs JFA, Kanski M, Arheden H, Olivecrona GK, Larsson B, Erlinge D. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord 2010;10: 45.
40. Arslan F, Smeets MB, O'Neill LAJ, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, De Kleijn DPV. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121: 80-90.
41. Timmers L, Van Keulen JK, Hoefer IE, Meijs MFL, Van Middelaar B, Den Ouden K, Van Echteld CJA, Pasterkamp G, De Kleijn DPV. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res 2009;104: 699-706.
42. Van der Pouw Kraan TCTM, Bernink FJP, Yildirim C, Koolwijk P, Baggen JM, Timmers L, Beek AM, Diamant M, Chen WJY, van Rossum AC, van Royen N, Horrevoets AJG, Appelman YE. Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute STelevation myocardial infarction. J Mol Cell Cardiol 2014;67: 94-102.
43. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu D-X. C5aR-mediated myocardial ischemia/ reperfusion injury. Biochem Biophys Res Commun 2007;357: 446-452.
44. Rabb H, Daniels F, DonnellMO, Haq M, Saba SR, KeaneW, TangWW. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Ren Physiol 2000;279: F525-F531.